Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy: primary…
- Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pembrolizumab in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02337686).
- Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy:…
- Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery: primary…
- Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002,…
- Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pemetrexed Plus Gemcitabine in Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Plus Gemcitabine in Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00491075).
- Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205): Complete Statistical AnalysisIndependent statistical analysis of Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pen PreferenceIndependent statistical analysis of Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus: primary endpoint results,…
- PENELOPE-BIndependent statistical analysis of A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery: primary endpoint results,…
- Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Penicillin De-labeling in the Pediatric Primary Care Setting: Complete Statistical AnalysisIndependent statistical analysis of Penicillin De-labeling in the Pediatric Primary Care Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05010304).
- Penile Nerve Stimulation for Treatment of Delayed Ejaculation: Complete Statistical AnalysisIndependent statistical analysis of Penile Nerve Stimulation for Treatment of Delayed Ejaculation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04115540).
- Penn State TXT2Quit Study: Complete Statistical AnalysisIndependent statistical analysis of Penn State TXT2Quit Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02367391).
- Penn State TXT2STAYQUIT Study- a Texting Study to Help Hospitalized Smokers Stay Quit: Complete Statistical AnalysisIndependent statistical analysis of Penn State TXT2STAYQUIT Study- a Texting Study to Help Hospitalized Smokers Stay Quit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PENNANTIndependent statistical analysis of An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia: primary endpoint results, effect estimate…
- PENSIndependent statistical analysis of Efficacy in iNPH Shunting (PENS) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05081128).
- Pento & tBUIndependent statistical analysis of Phase II Trial of Pentostatin and Targeted Busulfan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496340).
- Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People: Complete Statistical AnalysisIndependent statistical analysis of Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pentoxifylline for Acute Alcoholic Hepatitis (AAH): Complete Statistical AnalysisIndependent statistical analysis of Pentoxifylline for Acute Alcoholic Hepatitis (AAH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00205049).
- Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH: Complete Statistical AnalysisIndependent statistical analysis of Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00267670).
- PEOPLEComplete statistical analysis of the PEOPLE phase 3 trial of post-exposure prophylaxis for leprosy in the Comoros and Madagascar, including trial design, incidence rate ratios, mixed-effects methodology, confidence intervals, and interpretation.
- PEOPLEIndependent statistical analysis of Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03662022).
- PEPIndependent statistical analysis of Patients Engaged in Prevention: Enhancing Outreach to Increase Patient Engagement in Diabetes Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PEP uP Protocol in Surgical Patients: Complete Statistical AnalysisIndependent statistical analysis of PEP uP Protocol in Surgical Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02459275).
- PEPIIndependent statistical analysis of Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00578864).
- PEPSIndependent statistical analysis of Prevention of Peritonitis in Peritoneal Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01293799).
- Peptide Vaccination for Patients at High Risk for Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Peptide Vaccination for Patients at High Risk for Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00059475).
- Perampanel in Seizure Patients With Primary Glial Brain Tumors: Complete Statistical AnalysisIndependent statistical analysis of Perampanel in Seizure Patients With Primary Glial Brain Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02363933).
- Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD: Complete Statistical AnalysisIndependent statistical analysis of Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04458103).
- Percutaneous US Guided Elbow Tenotomy With the TenJet HydroSurgery System: Complete Statistical AnalysisIndependent statistical analysis of Percutaneous US Guided Elbow Tenotomy With the TenJet HydroSurgery System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03487250).
- PERFECT OLEIndependent statistical analysis of Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PERFECTIONIndependent statistical analysis of Evaluation of FUSION™ Vascular Graft for Above Knee Targets: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01601496).
- Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study): Complete Statistical AnalysisIndependent statistical analysis of Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study): primary endpoint results, effect estimate with confidence interval,…
- Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED): Complete Statistical AnalysisIndependent statistical analysis of Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…